Class Action Lawsuit Alert Issued for Applied Therapeutics Investors
Bronstein, Gewirtz & Grossman, LLC, a prominent law firm specializing in class actions, announces that they are representing investors in a newly filed class action lawsuit against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers. If you have incurred substantial losses due to your investments in Applied Therapeutics, you might have the opportunity to take action.
Understanding the Class Definition
The class action seeks to recover damages for investors who purchased or acquired Applied Therapeutics securities within a specific time frame. This includes all individuals and entities who made transactions between January 3, 2024, and December 2, 2024, which is referred to as the “Class Period.” If you fall within this category, you are urged to join the case at the firm’s official website.
Key Details of the Case
The allegations put forth in the complaint claim that during the Class Period, the Defendants engaged in misleading practices relating to the company’s New Drug Application (NDA) for govorestat. Allegedly, the NDA had significant deficiencies that would undermine its approval by the FDA. Furthermore, the clinical data presented in support of the NDA is said to have been inadequate to prove efficacy or safety. As a result, statements made by Applied Therapeutics regarding the likelihood of approval were misleading. Consequently, the public representations made by the Company were substantially false or lacked reasonable support at the time.
Next Steps for Affected Investors
If you are an investor who suffered losses in Applied Therapeutics, there are measures you can take. A formal class action lawsuit is already underway. Interested parties may visit the firm’s website to review a copy of the Complaint. Alternatively, you can reach out to Peretz Bronstein, Esq. or Client Relations Manager, Nathan Miller, at 332-239-2660. Please note that to be appointed as the lead plaintiff, you must act before a specified deadline, which is currently set for February 18, 2025. However, your ability to participate in any potential recovery does not hinge on being the lead plaintiff.
No Financial Obligation for You
Legal representation by Bronstein, Gewirtz & Grossman, LLC is offered on a contingency fee basis. This means that you will not be charged unless the court rules in favor of your case. Expenses and legal fees are usually deducted from the total recovery only if the litigation concludes successfully.
Why Choose Bronstein, Gewirtz & Grossman?
This law firm has established itself as a leader in representing investors within the realm of securities fraud class actions and shareholder derivative lawsuits. Over the years, Bronstein, Gewirtz & Grossman has successfully recovered hundreds of millions of dollars for their clients across the nation, showcasing their commitment and expertise in advocating for investors.
Keep abreast of updates related to your rights and options by following Bronstein, Gewirtz & Grossman, LLC on popular social media platforms like LinkedIn, X, Facebook, and Instagram.
Frequently Asked Questions
What is the lawsuit about?
The lawsuit is aimed at recovering losses for investors who purchased Applied Therapeutics securities between specified dates, alleging violations of federal securities laws.
How can I join the class action?
You can join the class action by visiting the law firm’s website for more details and signing up if you qualify.
What are the implications of this lawsuit?
The lawsuit seeks to hold Applied Therapeutics accountable for any misleading statements made during the Class Period which may have caused investor losses.
What should I do if I am affected?
If you have suffered losses, consider reviewing the Complaint and contacting the law firm for your potential involvement in the case.
Is there any cost associated with joining the lawsuit?
No, there is no upfront cost to you. Legal fees are taken from any recovery obtained through the case.
